CardioVascular Business Overview

CardioVascular accounted for $2.1 billion, or 16%, of Medtronic's $13.5 billion in revenue in FY2008.

FY2008 Global Revenue
CardioVascular accounted for $2.1 billion, or 16%, of Medtronic's $13.5 billion in revenue in FY2008.

CardioVascular is Medtronic's third-largest business. As hospitals and healthcare organisations increasingly encourage collaboration between cardiovascular specialties, Medtronic continues to serve as a key resource. Our therapies span the major specialties of interventional cardiology, cardiac surgery, and vascular surgery.

Our products, developed in collaboration with leading doctors, are used to reduce the potentially debilitating effects of coronary, aortic, and structural heart disease. These products include:

  • Angioplasty technologies to treat arteries that are blocked by atherosclerotic plaque and restore blood flow to the heart.
  • Stent grafts to treat aortic aneurysms.
  • Heart valves and valve repair technology to treat congenital heart defects and valve disease. We also continually work to develop minimally invasive approaches to traditional full open-chest heart surgery for valve replacement and repair.
  • Open-heart and coronary bypass graft products to restore blood flow to the heart.

Medtronic Educational Program

Our EDGE program offers a variety of multi-faceted training events designed to expand the skills of cardiac surgeons and enable them to thrive as cardiovascular specialties draw from one another to improve patient care. Through the programs, surgeons work with leading experts in many areas, including virtual catheter lab training, complex mitral repair, minimally invasive valve surgery, robotic surgical techniques, and beating heart strategies.

Last updated: 27 Sep 2010

Section Navigation

Additional information

NYSE (MDT)

Australasia